Table 1 Uncontaminated ADPHFs used in study
From: Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization
Tau | Tau/total protein | Aβ 1–40 | Aβ 1–40/total protein | Aβ 1–42 | Aβ 1–42/total protein | |
|---|---|---|---|---|---|---|
mg/ml | mg/ml | mg/ml | ||||
AD case 1 | 2.1 | 25.69% | 0.000022 | 0.0002% | 0.000102 | 0.0012% |
AD case 2 | 0.61 | 11.29% | 0.000016 | 0.0003% | 0.000083 | 0.0015% |
AD case 3 | 0.4 | 14.29% | 0.000032 | 0.0011% | 0.000060 | 0.0021% |
AD case 4 | 0.53 | 18.28% | 0.000003 | 0.0001% | 0.000061 | 0.0021% |
AD case 5 | 0.47 | 27.65 | 0.000010 | 0.0005% | 0.000095 | 0.0056% |